BioSpecifics Technologies Corp. (NASDAQ:BSTC) released its earnings data on Thursday. The company reported $0.25 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.17 by $0.08, Stock Ratings Network.com reports. BioSpecifics Technologies Corp. (NASDAQ:BSTC) stock performance was 1.56% in last session and finished the day at $26.72. Traded volume was 32,149.00 shares in the last session and the average volume of the stock remained 27,462.00 shares. The beta of the stock remained 0.90. BioSpecifics Technologies Corp. (NASDAQ:BSTC) insider ownership is 1.40%.
NanoString Technologies (NASDAQ:NSTG) had its target price boosted by Robert W. Baird from $23.00 to $26.00 in a report issued on Wednesday, AR Network reports. NanoString Technologies Inc. (NASDAQ:NSTG) dropped -2.77% to $21.38 yesterday on volume of 115,011.00 shares. The intra-day range of the stock was $20.82 – $22.44. NanoString Technologies Inc. (NASDAQ:NSTG) has a market capitalization of 312.49 million.
Celladon Corp (NASDAQ:CLDN) on Mar. 4 announced it has completed enrollment and randomized 250 patients in the phase 2b trial titled “Calcium Up-Regulation by Percutaneous Administration of Gene Therapy In Cardiac Disease,” known as CUPID 2, which is evaluating the efficacy and safety of MYDICAR (AAV1/SERCA2a) in patients with NYHA class III/IV symptoms of systolic heart failure. Celladon Corp (NASDAQ:CLDN)’s stock on March 13, 2014 reported a higher of 8.27% to the closing price of $14.66. Its fifty two weeks range is $7.45 – $15.48. The total market capitalization recorded 250.82 million. The overall volume in the last trading session was 225,698.00 shares. In its share capital, Celladon Corp (NASDAQ:CLDN) has 17.11 million outstanding shares.
Receptos Inc. (NASDAQ:RCPT) on Mar. 5 provided development program updates and announced financial results for the fourth quarter and year ended December 31, 2013. On Thursday, shares of Receptos Inc. (NASDAQ:RCPT) dropped -4.99% to close the day at $50.45. Company return on investment (ROI) is 44.50% and its monthly performance is recorded as 15.55%. Receptos Inc. (NASDAQ:RCPT) quarterly revenue growth is 85.07%.